Behavioral Phenotypes for Negative Symptoms in Animal Models of Schizophrenia

Abstract.: A devastating psychiatric disorder, schizophrenia is characterized by three major symptoms, positive and negative symptoms and cognitive deficit. Almost all current therapeutic drugs for schizophrenia have efficacy for positive symptoms, and weak efficacy for negative and cognitive defici...

Full description

Bibliographic Details
Main Authors: Yoshiaki Miyamoto, Atsumi Nitta
Format: Article
Language:English
Published: Elsevier 2014-04-01
Series:Journal of Pharmacological Sciences
Online Access:http://www.sciencedirect.com/science/article/pii/S1347861319300891
id doaj-16581d9ebde44de396c12f184a9fe86a
record_format Article
spelling doaj-16581d9ebde44de396c12f184a9fe86a2020-11-25T01:56:44ZengElsevierJournal of Pharmacological Sciences1347-86132014-04-011264310320Behavioral Phenotypes for Negative Symptoms in Animal Models of SchizophreniaYoshiaki Miyamoto0Atsumi Nitta1Department of Pharmaceutical Therapy & Neuropharmacology, Faculty of Pharmaceutical Sciences, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan; Corresponding author. miyamoto@pha.u-toyama.ac.jpDepartment of Pharmaceutical Therapy & Neuropharmacology, Faculty of Pharmaceutical Sciences, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama 930-0194, JapanAbstract.: A devastating psychiatric disorder, schizophrenia is characterized by three major symptoms, positive and negative symptoms and cognitive deficit. Almost all current therapeutic drugs for schizophrenia have efficacy for positive symptoms, and weak efficacy for negative and cognitive deficit. In particular, social withdrawal, diminished motivation, and anhedonia as the depressive aspects of negative symptoms are resistant to the treatment of antipsychotic drugs. Therefore, there is a need for development of new therapeutic drugs for negative symptoms of schizophrenia, and it is necessary to have comprehensive animal models to understand the neurobiological foundations of their symptoms. In this review, we represent the behavioral phenotypes in available animal models of schizophrenia for drug discovery, focusing on the depressive aspects of negative symptoms. We mention here animal models based on the pathology and epidemiology of schizophrenia, e.g., the pharmacological, neurodevelopmental, genetic, and gene-environment combination models. The animal models of schizophrenia are developed by various approaches and are assessed, but there are few models demonstrating negative symptoms with sensitivities to available therapeutic drugs. The development of comprehensive animal model reflecting negative symptoms and of novel compounds that can remedy them provide certain insight into the neurobiological process of schizophrenia and also point the way to a new therapeutic strategy. Keywords:: schizophrenia, social withdrawal, diminished motivation, anhedonia, animal modelshttp://www.sciencedirect.com/science/article/pii/S1347861319300891
collection DOAJ
language English
format Article
sources DOAJ
author Yoshiaki Miyamoto
Atsumi Nitta
spellingShingle Yoshiaki Miyamoto
Atsumi Nitta
Behavioral Phenotypes for Negative Symptoms in Animal Models of Schizophrenia
Journal of Pharmacological Sciences
author_facet Yoshiaki Miyamoto
Atsumi Nitta
author_sort Yoshiaki Miyamoto
title Behavioral Phenotypes for Negative Symptoms in Animal Models of Schizophrenia
title_short Behavioral Phenotypes for Negative Symptoms in Animal Models of Schizophrenia
title_full Behavioral Phenotypes for Negative Symptoms in Animal Models of Schizophrenia
title_fullStr Behavioral Phenotypes for Negative Symptoms in Animal Models of Schizophrenia
title_full_unstemmed Behavioral Phenotypes for Negative Symptoms in Animal Models of Schizophrenia
title_sort behavioral phenotypes for negative symptoms in animal models of schizophrenia
publisher Elsevier
series Journal of Pharmacological Sciences
issn 1347-8613
publishDate 2014-04-01
description Abstract.: A devastating psychiatric disorder, schizophrenia is characterized by three major symptoms, positive and negative symptoms and cognitive deficit. Almost all current therapeutic drugs for schizophrenia have efficacy for positive symptoms, and weak efficacy for negative and cognitive deficit. In particular, social withdrawal, diminished motivation, and anhedonia as the depressive aspects of negative symptoms are resistant to the treatment of antipsychotic drugs. Therefore, there is a need for development of new therapeutic drugs for negative symptoms of schizophrenia, and it is necessary to have comprehensive animal models to understand the neurobiological foundations of their symptoms. In this review, we represent the behavioral phenotypes in available animal models of schizophrenia for drug discovery, focusing on the depressive aspects of negative symptoms. We mention here animal models based on the pathology and epidemiology of schizophrenia, e.g., the pharmacological, neurodevelopmental, genetic, and gene-environment combination models. The animal models of schizophrenia are developed by various approaches and are assessed, but there are few models demonstrating negative symptoms with sensitivities to available therapeutic drugs. The development of comprehensive animal model reflecting negative symptoms and of novel compounds that can remedy them provide certain insight into the neurobiological process of schizophrenia and also point the way to a new therapeutic strategy. Keywords:: schizophrenia, social withdrawal, diminished motivation, anhedonia, animal models
url http://www.sciencedirect.com/science/article/pii/S1347861319300891
work_keys_str_mv AT yoshiakimiyamoto behavioralphenotypesfornegativesymptomsinanimalmodelsofschizophrenia
AT atsuminitta behavioralphenotypesfornegativesymptomsinanimalmodelsofschizophrenia
_version_ 1724978250834247680